Sionna Therapeutics, Inc.
SION Nasdaq
SEC CIK 2036042
Follow Sionna Therapeutics
Weekly email: filings, results
Net income
−$32.4M
−59.9% vs same quarter last year
EPS, diluted
−$0.72
−56.5% vs same quarter last year
Operating cash flow
−$18.7M
−22.9% vs same quarter last year
Operating income
−$34.8M
−46.3% vs same quarter last year
Source: SEC XBRL filings · latest filing